Livzon Pharmac Grp Stock Net Income

LP6 Stock  EUR 3.40  0.18  5.59%   
LIVZON PHARMAC GRP fundamentals help investors to digest information that contributes to LIVZON PHARMAC's financial success or failures. It also enables traders to predict the movement of LIVZON Stock. The fundamental analysis module provides a way to measure LIVZON PHARMAC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to LIVZON PHARMAC stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

LIVZON PHARMAC GRP Company Net Income Analysis

LIVZON PHARMAC's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current LIVZON PHARMAC Net Income

    
  684.16 M  
Most of LIVZON PHARMAC's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, LIVZON PHARMAC GRP is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Based on the recorded statements, LIVZON PHARMAC GRP reported net income of 684.16 M. This is 100.47% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers-Specialty & Generic industry. The net income for all Germany stocks is 19.82% lower than that of the firm.

LIVZON Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses LIVZON PHARMAC's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of LIVZON PHARMAC could also be used in its relative valuation, which is a method of valuing LIVZON PHARMAC by comparing valuation metrics of similar companies.
LIVZON PHARMAC is currently under evaluation in net income category among its peers.

LIVZON Fundamentals

About LIVZON PHARMAC Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze LIVZON PHARMAC GRP's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of LIVZON PHARMAC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of LIVZON PHARMAC GRP based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in LIVZON Stock

LIVZON PHARMAC financial ratios help investors to determine whether LIVZON Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in LIVZON with respect to the benefits of owning LIVZON PHARMAC security.